Business combinations (Tables)

Kai Pharmaceuticals [Member]

The consideration to acquire KAI totaled $332 million in cash which was allocated to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):



Indefinite-lived intangible assets - IPR&D	$	240
Goodwill	125
Deferred tax assets (liabilities), net	(59		)
Other assets (liabilities), net	26
Total consideration	$	332

Mustafa Nevzat Pharmaceuticals [Member]

The consideration to acquire MN totaled $677 million in cash which was allocated to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):



Finite-lived intangible assets	$	163
Property, plant and equipment	100
Trade receivables	79
Inventories	52
Goodwill	380
Deferred tax assets (liabilities), net	(45		)
Other assets (liabilities), net	(52		)
Total consideration	$	677

Micromet Inc [Member]

The consideration to acquire Micromet totaled $1,146 million in cash which was allocated to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):



Indefinite-lived intangible assets:
IPR&D	$	440
Contract assets	170
Finite-lived intangible assets — Developed technology	350
Goodwill	330
Cash and marketable securities	154
Deferred tax assets (liabilities), net	(274		)
Other assets (liabilities), net	(24		)
Total consideration	$	1,146

Biovex Group Inc [Member]

The aggregate acquisition date consideration to acquire BioVex consisted of (in millions):



Cash paid to former shareholders of BioVex	$	407
Fair value of contingent consideration obligations	190
Total consideration	$	597

We allocated the total consideration to the acquisition date fair values of assets acquired and liabilities assumed as follows (in millions):



Indefinite-lived intangible assets — IPR&D	$	675
Goodwill	170
Deferred tax assets (liabilities), net	(246		)
Other assets (liabilities), net	(2		)
Total consideration	$	597